In a 71-year-old male swing-bed patient with advanced dementia who is taking mirtazapine 15 mg at bedtime, buspirone 7.5 mg twice daily, donepezil 10 mg at bedtime, lorazepam (Ativan) 0.25 mg twice daily and as needed twice daily, ramelteon 16 mg at bedtime, and acetaminophen 650 mg twice daily and as needed every 6 hours, what is the appropriate antipsychotic to manage his increasingly worsening behaviors?

Antipsychotic Selection for Behavioral Symptoms in Advanced Dementia

Direct Recommendation

Before initiating any antipsychotic, you must first discontinue lorazepam (Ativan) and attempt dose reduction of mirtazapine, as both medications are likely worsening this patient's behavioral symptoms and carry significant mortality risk in dementia. 1234

Critical First Steps: Medication Optimization

Immediate Actions Required

Taper and discontinue lorazepam:

• Benzodiazepines paradoxically worsen agitation in dementia patients and increase fall risk, cognitive decline, and mortality 3
• The patient is receiving 0.5 mg daily scheduled PLUS additional PRN doses—this is excessive and contraindicated
• Taper by 25% every 3-5 days to avoid withdrawal

Reduce or discontinue mirtazapine 15 mg:

• A 2021 randomized controlled trial (SYMBAD) demonstrated mirtazapine showed no benefit for agitation in dementia compared to placebo 4
• More concerning: 7 deaths occurred in the mirtazapine group versus 1 in placebo by week 16 (p=0.065) 4
• This medication is likely contributing to, not helping, the behavioral symptoms
• The FDA label warns of serotonin syndrome risk when combined with buspirone, which this patient is taking 56

Drug Interaction Concerns

The current regimen has dangerous interactions:

• Mirtazapine + buspirone = increased serotonin syndrome risk 56
• Adding an antipsychotic to this combination further increases QT prolongation and serotonin syndrome risk 5

When Antipsychotics Are Appropriate

APA guidelines state antipsychotics should only be used when symptoms are severe, dangerous, and/or cause significant distress 1. The guidelines mandate:

1. Document that non-pharmacological interventions have been attempted 12
2. Assess for pain and medical contributors (UTI, constipation, medication side effects) 1
3. Discuss risks/benefits with surrogate decision maker, including increased mortality risk 1

Antipsychotic Selection Algorithm

If antipsychotic treatment is deemed necessary after the above steps:

First-Line Choice: Risperidone 0.25-0.5 mg daily

• Strongest evidence for aggression and psychosis in dementia 17
• Start 0.25 mg once daily, titrate to 0.5-1 mg maximum 1
• Most studied antipsychotic with FDA acknowledgment of efficacy (though not approved) 7

Second-Line Choice: Quetiapine 12.5-25 mg daily

• Start 12.5 mg at bedtime, titrate slowly 8
• Most commonly prescribed in clinical practice (93.1% of antipsychotic prescriptions in one study) 8
• Shorter half-life and fewer anticholinergic effects than alternatives 9
• Better tolerated in Lewy body features (if present)

Avoid:

• Olanzapine - high anticholinergic burden worsens cognition
• Haloperidol - high extrapyramidal symptoms in elderly

Monitoring Requirements

Mandatory 4-week trial period 1:

• Use quantitative measure (CMAI or NPI) to assess response 1
• If no clinically significant response after 4 weeks at adequate dose, taper and discontinue 1
• If significant side effects occur, reassess risk/benefit and consider discontinuation 1

Monitor for:

• Sedation, falls, stroke symptoms
• Extrapyramidal symptoms (rigidity, tremor)
• QT prolongation (baseline and follow-up ECG if risk factors present)
• Mortality risk discussion documented

Critical Pitfalls to Avoid

1. Do not add an antipsychotic without first removing lorazepam - you will compound sedation, falls, and mortality risk
2. Do not continue mirtazapine for agitation - evidence shows harm without benefit 4
3. Do not use antipsychotics long-term - reassess need every 3-4 months for dose reduction or discontinuation 1
4. Do not skip non-pharmacological interventions - music therapy, structured activities, addressing unmet needs (toileting, hunger, pain) 2

Practical Implementation

Week 1-2: Begin lorazepam taper, assess for pain/medical causes, implement behavioral interventions

Week 2-3: Consider mirtazapine taper given lack of efficacy and mortality signal

Week 3-4: If behaviors remain severe/dangerous after medication optimization, initiate risperidone 0.25 mg daily with documented informed consent

Week 8: Reassess with quantitative measure; discontinue if ineffective 1